Bio-Rad Laboratories, Inc. Class A Common Stock vs Fidelity National Information Servcs Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Fidelity National Information Servcs Inc trades at $41.2 (market cap $20.97B). The key difference: Fidelity National Information Servcs Inc is far larger — about 2.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | FIS | |
|---|---|---|
Market Cap | $8.04B | $20.97B |
Sector | Health | Technology |
52-Week High | $339.75 | $81.94 |
52-Week Low | $241.71 | $37.72 |
Enterprise Value | $7.85B | $41.37B |
Dividend Yield | — | 4.14% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FIS trades at $41.93, down 0.12% on the day, with a bullish technical signal from moving averages and strong institutional support. The stock shows attractive valuation metrics with a P/E of 8.13 and P/S of 1.91, while recent earnings have generally beaten expectations. Positive news flow highlights FIS's leadership in AI-driven banking technology and cloud infrastructure, with upcoming Q2 2026 earnings on August 4, 2026, providing a near-term catalyst.
The outlook for FIS is positive given its low valuation, analyst consensus price target of $52.57 (25% upside), and strategic focus on digital banking growth. Key risks include execution challenges post-Worldpay divestiture and rising debt levels, but strong cash flow generation and dividend yield of approximately 1.05% support shareholder returns. Institutional sentiment remains bullish with 58% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →